• Explore /
  • Poster
  • / A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.

A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.

Abstract Poster

Authors

null

Joshua Bauml

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Joshua Bauml , Natalie Sophia Grover , Amy Ronczka , Daniel Cushing , Michael Klichinsky , Debora Barton , Elizabeth Claire Dees

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT04660929

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2660)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2660

Abstract #

TPS2660

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Kim Anna Reiss

First Author: Kim Anna Reiss

First Author: Behnam Badie

First Author: Shanshan Jin